Prascend (pergolide mesylate), dopamine receptor agonist, is the first and only FDA-approved treatment for the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (Equine Cushing’s Disease) in horses. Each tablet contains 1 mg of pergolide mesylate. For oral use in horses.
Prascend (pergolide mesylate), 1 mg tab
From $209.50Sale Price
0/100
%2C+1+mg+tab){kind=link}